Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Theravance Biopharma (TBPH) yesterday and set a price target of $55. The company’s shares closed yesterday at $27.05.
Chen wrote:
“: Based on our discussions with leading physicians that treat UC and Crohn’s, we think the market opportunity for TBPH’s TD-1473 is underappreciated. The physicians we have spoken with believe that TD-1473 could be the leading drug to treat UC and Crohn’s because of its efficacy and safety profile. These doctors think that the Phase 2/3 studies are properly designed, adequately powered and that TBPH has chosen the right doses. The takeaways from our calls with these doctors support our OW rating and $55 PT for TBPH shares.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 4.6% and a 33.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Theravance Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $46.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $35.48 and a one-year low of $21.27. Currently, Theravance Biopharma has an average volume of 225K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Theravance Biopharma, Inc. operates as a biopharmaceutical company, which focuses on the discovery, development and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
